HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Sales Continue In University Vending Machine, Unlikely To Spread

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will not move to stop Plan B sales via vending machine at a college health clinic where the population is of a legal age to buy the product without a prescription. While the decision could open a door for a limited number of copycats, the landscape for nonprescription emergency contraception remains limited.

You may also be interested in...



Barriers To US OTC Emergency Contraceptive Sales Remain Despite Court Rebuke Of Restrictions

Continuing impediments include pharmacists and other staff at drug and grocery stores refusing to sell emergency contraceptives, some stores stocking products in locked display cabinets and prices unaffordable to some consumers, says Kelly Cleland, American Society for Emergency Contraception executive director.

In Brief

OTC HIV tests inch closer; FDA investigates Plan B vending machine; Crest toothpaste brightens in one use; L’Oreal sues J&J, Merck for sunscreen patent infringement; more News In Brief.

With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics

Teva Pharmaceutical Industries likely will gain another three years of exclusivity in the branded nonprescription emergency contraceptive market with FDA's approval of a revised dosage of Plan B

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel